EMBC — Embecta Corp. Stock Price, Chart & AI Report

Negative Jul 15, 2026 • 22:32 UTC GlobeNewswire Inc. • Hagens Berman

Embecta Corp. (EMBC) Faces Securities Class Action Over Alleged Concealed Material Risks to Pen Needle Revenue– HBSS

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. Embecta slashed its full-year EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

EMBC securities class action pen needle revenue misleading guidance earnings miss dividend cut shareholder losses medical device company

Sentiment note

Company allegedly concealed material risks regarding pen needle market weakness while providing reassuring guidance. Q2 2026 results showed a 61% EPS decline versus guidance, massive revenue declines, 43% full-year guidance reduction, and 93% dividend cut, resulting in substantial shareholder losses and triggering a securities class action lawsuit.

Negative Jul 14, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Embecta Corp. alleging that the company made materially false and misleading statements about its business and guidance during the period from November 25, 2025 to May 4, 2026. The complaint claims Embecta's pen needle business guidance was unattainable, and the company subsequently missed Q2 2026 expectations with a 14% revenue decline and lowered full-year guidance.

EMBC class action lawsuit securities fraud misleading guidance revenue decline pen needle business investor harm

Sentiment note

The company is accused of making materially false and misleading statements about its business prospects and guidance. It touted its pen needle business as 'incredibly resolute' before missing Q2 2026 expectations with a 14% revenue decline, significantly worse than the guided 0-2% decline, resulting in lowered full-year 2026 guidance.

Negative Jul 13, 2026 • 20:48 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EMBC

Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp., Nano-X Imaging Ltd., and Lucid Group, Inc. during specified periods to join securities class action lawsuits. The lawsuits allege that these companies made false or misleading statements regarding financial guidance and business performance. Investors with losses exceeding $100,000 are encouraged to secure counsel before the August 17, 2026 lead plaintiff deadline.

EMBC NNOX LCID securities class action investor losses misleading statements financial guidance lead plaintiff deadline

Sentiment note

Company is subject to securities class action lawsuit alleging false/misleading statements about fiscal results and pen needle business guidance that proved unattainable, resulting in investor losses.

Negative Jul 13, 2026 • 17:33 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Embecta Corp. faces a securities fraud class action lawsuit after revealing a 14% revenue decline due to weakness in pen needle sales and lowering fiscal 2026 guidance on May 5, 2026. The stock plummeted 57.8% to $3.90 per share. Defendants are accused of making materially false statements and failing to disclose material adverse facts about the company's business and prospects during the Class Period (November 25, 2025 - May 4, 2026). The deadline to file a lead plaintiff motion is August 17, 2026.

EMBC securities fraud class action lawsuit revenue decline pen needle sales stock price drop misleading guidance lead plaintiff deadline

Sentiment note

The company faces securities fraud allegations, experienced a 57.8% stock price decline following disappointing Q2 2026 results with 14% revenue decline, and is accused of making materially false statements and failing to disclose material adverse facts about its business operations and prospects.

Negative Jul 11, 2026 • 12:33 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

EMBC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

EMBC securities fraud class action lawsuit misleading guidance stock price decline pen needle business lead plaintiff deadline

Sentiment note

The company is accused of making materially false and misleading statements about its financial guidance and business performance. A 57.8% single-day stock price decline following missed guidance and revenue shortfalls significantly exceeding projections indicates serious investor losses and loss of confidence in management's credibility.

Negative Jul 10, 2026 • 17:45 UTC GlobeNewswire Inc. • Hagens Berman

Embecta Corp. (EMBC) Faces Securities Class Action Over Alleged Concealed Material Risks to Pen Needle Revenue– HBSS

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. The company slashed full-year EPS guidance by 43% and cut its dividend by 93%, prompting investigations into whether management knew about revenue headwinds but failed to disclose them.

EMBC securities class action pen needle revenue misleading guidance earnings miss dividend cut investor losses disclosure violations

Sentiment note

Company faces securities litigation for allegedly concealing material risks and providing misleading forward guidance. Q2 2026 results showed a 61% EPS decline versus guidance, massive pen needle revenue declines, 43% full-year guidance reduction, and 93% dividend cut, indicating severe operational deterioration and potential management credibility issues.

Negative Jul 10, 2026 • 17:00 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for EMBC, FSLR, GTM, BTU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Embecta Corp., First Solar Inc., ZoomInfo Technologies Inc., and Peabody Energy Corporation. The lawsuits allege that defendants made false or misleading statements regarding business guidance, operational performance, and market conditions. Investors have until mid-to-late August 2026 to file lead plaintiff motions.

EMBC FSLR GTM BTU securities fraud class action lawsuit misleading statements investor losses

Sentiment note

Company faces allegations of misleading guidance and undisclosed segment weakness in the U.S. pen needle market, which undermined revenue projections and Q2 2026 results.

Negative Jul 10, 2026 • 10:18 UTC GlobeNewswire Inc. • Bleichmar Fonti & Auld Llp

Embecta (NASDAQ:EMBC) Insulin Pen Issues Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit

A securities fraud class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) after its stock plummeted 57.8% on May 5, 2026. The company allegedly misled investors about the strength of its insulin pen needle product portfolio, claiming resilience while facing significant competition and market softness. The disappointing Q2 2026 results revealed share loss in the pen needle category and led to a dividend reduction from $0.15 to $0.01 per share.

EMBC securities fraud class action lawsuit insulin pen medical device stock decline misleading statements dividend reduction

Sentiment note

Company faced a 57.8% stock price decline due to disappointing Q2 2026 results, significant share loss in pen needle category, market softness admissions, dividend reduction from $0.15 to $0.01 per share, and allegations of misleading investors about product portfolio strength.

Negative Jul 7, 2026 • 22:30 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EMBC

Rosen Law Firm announces a securities class action lawsuit against Embecta Corp., alleging the company made false and misleading statements about its fiscal results and pen needle business guidance. Investors who purchased EMBC stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 17, 2026.

EMBC securities class action Embecta Corp. misleading guidance investor compensation lead plaintiff deadline pen needle business

Sentiment note

The company is accused of making false and misleading statements about fiscal results and providing unattainable guidance. The lawsuit alleges Embecta touted its pen needle business as 'incredibly resolute' before missing expectations and cutting 2026 guidance, resulting in investor damages.

Negative Jul 7, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Embecta Corp. alleging that the company made materially false and misleading statements about its business and guidance during the period from November 25, 2025 to May 4, 2026. The complaint claims Embecta's pen needle business guidance was unattainable, and the company subsequently missed Q2 2026 expectations with a 14% revenue decline and lowered full-year guidance.

EMBC class action lawsuit securities fraud misleading guidance revenue decline pen needle business investor harm

Sentiment note

The company is accused of making materially false and misleading statements about its business and guidance. It failed to meet Q2 2026 guidance with a 14% revenue decline (versus guidance of flat to 2% decline) and subsequently lowered full-year 2026 guidance, particularly due to weakness in pen needle sales.

Negative Jul 6, 2026 • 21:20 UTC GlobeNewswire Inc. • Hagens Berman

Embecta Corp. (EMBC) Faces Securities Class Action Over Alleged Concealed Material Risks to Pen Needle Revenue – HBSS

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. The company slashed its 2026 EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

EMBC securities class action pen needle revenue misleading guidance earnings miss dividend cut shareholder losses medical device company

Sentiment note

The company allegedly concealed material risks regarding its core pen needle business, provided misleading assurances about market stability, and subsequently reported a catastrophic 61% EPS decline with massive revenue declines, resulting in significant shareholder losses and a 93% dividend cut.

Negative Jul 5, 2026 • 13:26 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

EMBC CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its pen needle business and financial guidance. On May 5, 2026, Embecta disclosed a revenue decline of over 14% versus guided flat to 2% decline, causing the stock to plummet 57.8% in a single day. Investors who purchased Embecta securities between November 25, 2025 and May 4, 2026 may be eligible to participate in the lawsuit, with the lead plaintiff deadline set for August 17, 2026.

EMBC securities fraud class action lawsuit misleading guidance pen needle business stock price decline lead plaintiff investor losses

Sentiment note

The company is accused of making materially false and misleading statements about its financial guidance and pen needle business performance. The company missed its own guidance significantly (14% revenue decline vs. flat to 2% guided), leading to a catastrophic 57.8% single-day stock price decline and triggering a securities class action lawsuit.